liposom
phospholipid
bilay
vesicl
repres
almost
ideal
carrier
system
prepar
synthet
vaccin
due
biodegrad
capac
protect
transport
molecul
differ
physicochem
properti
includ
size
hydrophil
hydrophob
charg
liposom
carrier
appli
invas
eg
im
sc
id
well
noninvas
transderm
mucos
rout
last
year
liposom
vaccin
technolog
matur
sever
vaccin
contain
liposomebas
adjuv
approv
human
veterinari
use
reach
late
stage
clinic
evalu
given
intensifi
interest
liposomebas
vaccin
import
understand
precis
liposom
interact
immun
system
stimul
immun
becom
clear
physicochem
properti
liposom
vaccin
method
antigen
attach
lipid
composit
bilay
fl
uiditi
particl
charg
properti
exert
strong
effect
result
immun
respons
chapter
discuss
aspect
liposom
vaccin
includ
effect
novel
emerg
immunomodul
incorpor
applic
metallochel
nanoliposom
develop
recombin
vaccin
lyme
diseas
present
suitabl
exampl
vaccinolog
scientifi
c
fi
eld
undergo
dramat
develop
sophist
techniqu
rapidli
grow
indepth
knowledg
immunolog
mechan
hand
exploit
fulli
potenti
protect
well
cure
diseas
vaccin
spite
great
success
like
erad
smallpox
lesser
extent
poliomyel
two
import
mileston
medic
histori
new
challeng
arisen
face
rapidli
chang
ecosystem
human
behaviour
everincreas
densiti
human
farm
anim
popul
high
degre
mobil
result
rapid
spread
pathogen
infect
peopl
anim
poverti
war
confl
ict
third
world
mani
factor
contribut
frequent
occurr
rapid
dissemin
new
well
old
infecti
diseas
three
infect
heavili
affl
ict
global
health
aid
tuberculosi
malaria
exampl
new
viral
pathogen
ebola
viru
sar
coronaviru
new
strain
infl
uenza
viru
mention
rapid
sequenc
genom
pathogen
lead
develop
sensit
molecular
diagnost
tool
augment
identifi
cation
express
recombin
antigen
target
futur
vaccin
special
fi
eld
repres
immunotherapi
cancer
anticanc
vaccin
could
power
weapon
longterm
effect
treatment
progress
vaccin
develop
tightli
connect
new
fi
nding
immunolog
also
molecular
biolog
biotechnolog
new
term
revers
vaccinolog
propos
rappuoli
describ
complex
genomebas
approach
toward
vaccin
design
comparison
convent
approach
requir
labori
process
attenu
inactiv
pathogen
select
individu
compon
import
induct
immun
respons
revers
vaccinolog
offer
possibl
use
genom
inform
deriv
silico
analys
direct
design
product
protect
antigen
use
recombin
technolog
approach
signifi
cantli
reduc
time
necessari
identifi
cation
antigen
develop
candid
vaccin
enabl
systemat
identifi
cation
potenti
antigen
even
pathogen
diffi
cult
current
imposs
cultur
cours
approach
limit
identifi
cation
protein
glycoprotein
antigen
omit
import
vaccin
compon
polysaccharid
glycolipid
princip
question
revers
vaccinolog
consist
identifi
cation
protect
antigen
present
main
hurdl
approach
nevertheless
protect
antigen
identifi
ed
enabl
scientist
system
classifi
antigen
develop
effici
prepar
virtual
pathogen
genom
sequenc
determin
subunit
vaccin
offer
superior
safeti
profi
le
manufactur
minim
risk
contamin
coupl
appropri
adjuv
also
focu
immun
respons
protect
highli
conserv
antigen
determin
may
elicit
potent
respons
natur
infect
vaccin
inactiv
attenu
pathogen
common
observ
process
elicit
adapt
immun
respons
antigen
stimul
agent
word
administr
absolut
pure
recombin
protein
antigen
synthet
peptid
antigen
gener
induc
specifi
c
immun
respons
therefor
need
potent
costimul
coadministr
appropri
adjuv
biocompat
carrier
system
applic
devic
vaccin
consist
highli
purifi
ed
antigen
particul
system
suppos
mediat
effi
cient
deliveri
antigenpres
cell
may
induc
infl
ammat
activ
innat
immun
lyme
diseas
frequent
zoonosi
europ
unit
state
diseas
may
progress
chronic
form
caus
damag
nervou
cardiovascular
system
joint
skin
eye
infect
patient
affect
prolong
work
disabl
even
perman
invalid
prevent
treatment
diseas
thu
becom
longterm
prioriti
medic
research
symptom
typic
lyme
diseas
known
sinc
begin
twentieth
centuri
acrodermat
chronica
atrophican
erythema
migran
lymphocytoma
meningopolyradiculoneur
nevertheless
aetiolog
agent
borrelia
burgdorferi
describ
quit
recent
basi
endem
juvenil
arthriti
accompani
erythema
migran
later
shown
b
burgdorferi
sensu
lato
complex
sever
sibl
speci
current
speci
distinguish
new
variant
identifi
ed
continu
number
borrelia
speci
probabl
fi
nal
least
three
speci
known
pathogen
human
b
burgdorferi
sensu
stricto
b
afzelii
b
garinii
number
annual
report
lyme
diseas
case
continu
increas
mani
geograph
area
may
due
actual
spread
diseas
altern
improv
diagnost
method
genu
borrelia
swellengrebel
member
famili
spirochaetacea
togeth
genera
leptospira
treponema
usa
one
caus
agent
b
burgdorferi
ss
describ
europ
two
speci
b
afzelii
b
garinii
common
borrelia
typic
spiralshap
cell
length
diamet
shape
caus
periplasmat
fl
agella
respons
high
motil
viscou
environ
like
connect
tissu
borrelia
lack
rigid
cell
wall
surfac
compos
mainli
lipoprotein
strictli
control
express
pattern
essenti
adapt
extern
condit
diseas
vector
charact
time
transmit
human
infect
tick
genu
ixod
borrelia
also
found
midgut
mosquito
blood
suck
insect
role
haematophag
insect
diseas
transmiss
still
unclear
reservoir
compet
describ
broad
spectrum
wildlif
anim
eg
rodent
genera
apodemu
clethrionomi
microtu
rattu
etc
squirrel
sciuru
sp
hare
lepu
sp
bird
genera
turdu
phasianu
cardu
fringilla
etc
human
termin
host
incap
spread
infect
lyme
diseas
three
stage
earli
localis
infect
earli
dissemin
infect
late
persist
infect
stage
develop
everi
infect
individu
appear
signifi
cant
portion
infect
asymptomat
cours
without
clinic
symptom
elev
level
antiborreliaspecifi
c
antibodi
fi
rst
stage
character
nonspecifi
c
symptom
includ
fever
chill
headach
lethargi
andor
muscl
joint
pain
accompani
erythema
migran
site
bacteri
entri
infect
elimin
host
immun
system
antibiot
treatment
may
dissemin
affect
central
nervou
system
mening
radiculopathi
seventh
cranial
nerv
palsi
cardiovascular
system
atrioventricular
heart
block
myopericard
late
persist
infect
may
develop
month
year
transmiss
commonli
affect
nervou
system
skin
joint
less
frequent
heart
eye
organ
treatment
lyme
diseas
base
applic
antibiot
adult
administr
doxycyclin
recommend
children
mainli
betalactam
antibiot
prescrib
treatment
advanc
form
cephalosporin
penicillin
g
recommend
longterm
usag
antibiot
persist
form
lyme
diseas
limit
effect
fi
rst
effort
design
vaccin
lyme
diseas
follow
shortli
discoveri
borrelia
aetiolog
agent
caus
diseas
first
experi
demonstr
immunogen
bacteri
whole
cell
lysat
later
specifi
c
protein
identifi
ed
recognis
host
immun
system
express
surfac
antigen
borrelia
highli
variabl
tick
host
borrelia
express
outer
surfac
protein
ospa
b
ospb
gene
code
protein
locat
within
one
operon
express
protein
depend
housekeep
sigma
factor
rpod
presum
function
ospa
ospb
adhes
tick
gut
epithelium
tick
start
blood
feed
vertebr
host
protein
downregul
time
express
protein
depend
altern
sigma
factor
rpo
induc
eg
ospc
ospf
decorinbind
protein
dbpa
dbpb
protein
requir
borrelia
transmiss
vertebr
initi
stage
vertebr
infect
later
stage
ospc
downregul
express
vlse
protein
vmplike
sequenc
express
induc
enabl
borrelia
escap
specifi
c
humor
respons
due
high
vlse
variabl
earli
humor
respons
borrelia
characteris
product
igm
antibodi
specifi
c
ospc
fl
agellin
bmpa
later
igg
antibodi
dbpa
vlse
aris
case
antibodi
ospa
ospb
detect
later
stage
diseas
subunit
vaccin
fi
rst
gener
base
ospa
antigen
highli
express
cultiv
lyme
diseas
spirochet
vitro
preclin
trial
vaccin
base
ospa
antigen
demonstr
protect
anim
model
ospa
antigen
produc
either
recombin
protein
lipoprotein
express
surfac
escherichia
coli
salmonella
typhimurium
mycobacterium
bovi
two
ospabas
vaccin
candid
develop
test
imulym
vaccin
pasteur
merieuxconnaught
base
purifi
ed
recombin
ospa
antigen
express
e
coli
lymerix
glaxosmithklin
contain
purifi
ed
recombin
ospa
b
burgdorferi
ss
vaccin
protein
adsorb
aluminium
hydroxid
clinic
trial
involv
peopl
lymerix
vaccin
found
confer
protect
immun
borrelia
adult
children
mild
moder
transient
advers
effect
base
result
lymerix
approv
food
drug
administr
fda
decemb
subsequ
hundr
vaccine
report
develop
autoimmun
side
effect
support
patient
advocaci
group
number
classact
lawsuit
fi
led
glaxosmithklin
alleg
vaccin
caus
health
problem
claim
investig
fda
us
center
diseas
control
cdc
found
connect
vaccin
autoimmun
complaint
despit
lack
evid
sale
plummet
lymerix
withdrawn
us
market
glaxosmithklin
februari
set
neg
media
coverag
fear
vaccin
side
effect
number
reason
slow
develop
lyme
diseas
vaccin
includ
reluct
pharmaceut
compani
get
burn
similar
way
lymerix
manufactur
other
argu
simpli
profi
tabl
drug
manufactur
treat
symptom
lyme
palli
give
antiinfl
ammatori
medic
pain
reliev
medic
antibiot
fail
address
patient
ailment
continu
avail
lyme
diseas
vaccin
dog
made
mani
peopl
question
motiv
drug
compani
psycholog
compon
mani
symptom
often
blame
lyme
diseas
unlik
human
medicin
sever
licens
veterinari
lyme
diseas
vaccin
avail
companion
pet
three
formul
b
burgdorferi
bacterin
merilym
merial
germani
galaxi
lyme
schere
plough
usa
lymevax
fort
dodg
usa
european
vaccin
base
combin
bacterin
b
garinii
b
afzelii
produc
dog
biocan
bioveta
czech
republ
also
avail
veterinari
subunit
vaccin
base
recombin
ospc
antigen
prolym
intervet
usa
recombitek
lyme
merial
usa
veterinari
vaccin
appli
twodos
immunis
scheme
booster
recommend
yearli
safeti
data
limit
minor
crossreact
heterolog
borrelia
speci
report
thu
poor
crossprotect
coverag
problem
current
avail
vaccin
second
gener
ospa
subunit
vaccin
base
recombin
ospa
genet
remov
potenti
crossreact
tcell
epitop
formerli
suspect
induct
autoimmun
develop
broadli
crossprotect
rospa
vaccin
must
address
issu
pertain
sequenc
variat
least
seven
serotyp
ospa
exist
multivalentchimer
ospa
protein
develop
molecular
clone
incorpor
protect
epitop
sever
ospa
serotyp
nevertheless
ospa
antigenbas
vaccin
requir
repeat
vaccin
keep
high
titr
specifi
c
antibodi
vaccine
serum
prevent
transfer
bacteria
tick
human
host
new
interest
antigen
vaccin
develop
tick
ferritin
respons
maintain
iron
homeostasi
iron
essenti
potenti
toxic
element
therefor
feed
tick
must
deal
challeng
enorm
iron
suppli
blood
meal
ferritin
iron
storag
protein
play
pivot
role
process
shown
vaccin
recombin
signifi
cantli
reduc
tick
infest
vaccin
rabbit
infect
ixod
ricinu
cattl
infect
rhipicephalu
microplu
rhipicephalu
annulatu
result
support
inclus
promis
candid
antigen
develop
new
antitick
vaccin
spite
fact
ferritin
antigen
deriv
borrelia
vaccin
antigen
prevent
longterm
feed
tick
transmiss
borrelia
well
ticktransmit
pathogen
host
aspect
ferritin
could
superior
ospa
interest
includ
develop
combin
multiantigen
vaccin
mention
sever
new
antigen
discov
studi
possibl
target
new
vaccin
focu
ospc
antigen
receiv
consider
attent
effort
develop
broadli
protect
lyme
diseas
vaccin
ospc
essenti
virul
factor
critic
establish
earli
infect
mammal
sequenc
protein
undergo
mutat
infect
ospc
kda
immunodomin
lipoprotein
anchor
spirochet
outer
membran
n
termin
tripalmitoyl
glycerylcystein
factor
complic
exploit
ospc
vaccin
candid
exist
ospc
variat
molecular
phylogenet
analys
reveal
ospc
sequenc
form
least
distinct
ospc
type
ospc
variat
aris
primarili
genet
exchang
recombin
hypermut
concomit
immun
select
owe
sequenc
variat
protect
rang
singl
ospcbas
vaccin
narrow
potenti
approach
solv
high
variabl
ospc
prepar
polyval
vaccin
contain
sever
ospc
variant
b
gener
recombin
chimer
protein
consist
protect
epitop
ospc
type
associ
diseas
c
combin
two
differ
recombin
immunogen
like
ospc
dbpa
fi
bronectinbind
protein
biotechnolog
point
view
fulllength
ospc
diffi
cult
express
high
yield
puriti
recombin
protein
remov
lipidis
signal
substanti
increas
yield
bacteri
cultur
puriti
recombin
ospc
protein
side
delipidis
rospc
exert
low
immunogen
strong
adjuvant
vaccin
formul
necessari
induc
specifi
c
antibodi
respons
especi
subclass
experiment
mice
import
effect
complement
activ
opsonis
effort
adher
requir
ospc
vaccin
develop
experiment
vaccin
base
functionalis
metallochel
nanoliposom
synthet
nonpyrogen
adjuv
deriv
muramyl
dipeptid
formul
induc
strong
immun
respons
experiment
mice
superior
aluminium
hydroxid
formul
owe
versatil
safeti
adjuv
liposom
thu
repres
promis
platform
develop
clinic
accept
vaccin
lyme
diseas
next
part
chapter
focus
liposomalbas
vaccin
numer
particul
deliveri
system
develop
phospholipid
bilay
vesicl
liposom
among
promis
gregoriadi
allison
fi
rst
report
use
liposom
immunolog
adjuv
sinc
time
liposom
relat
vesicular
carrier
establish
robust
system
induct
humor
cellmedi
immun
broad
spectrum
infecti
diseas
cancer
liposom
repres
oldest
nanoparticl
system
describ
applic
biolog
studi
model
membran
medicin
year
liposom
shown
suitabl
drug
deliveri
system
applic
rang
cosmet
dermatolog
medic
applic
therapi
infect
anticanc
therapi
veterinari
vaccin
liposomebas
vaccin
around
approxim
year
numer
liposom
variant
develop
evid
immunestimulatori
properti
attract
safeti
profi
le
result
registr
sever
product
market
progress
other
advanc
stage
clinic
test
epax
crucel
hepat
formalininactiv
hepat
viru
adsorb
virosom
infl
exal
v
crucel
infl
uenza
virosom
reconstitut
infl
uenza
viral
membran
two
exampl
market
liposomebas
vaccin
human
applic
infl
exal
v
licens
countri
million
dose
appli
furthermor
least
eight
liposomebas
adjuv
system
current
approv
human
use
undergo
clinic
evalu
liposom
repres
almost
ideal
carrier
deliveri
system
compon
synthet
vaccin
due
biodegrad
abil
retainincorpor
varieti
essenti
vaccin
compon
simultan
even
compon
possess
quit
differ
physicochem
properti
differ
size
hydrophob
charg
etc
differ
synthet
vaccin
compon
encapsul
within
aqueou
caviti
liposom
hydrophil
associ
liposom
bilay
least
partial
hydrophob
charact
furthermor
essenti
compon
attach
either
intern
extern
outer
leafl
et
membran
electrostat
coval
metallochel
interact
biochem
divers
vaccin
compon
adjuv
requir
effi
caciou
activ
innat
immun
cell
includ
antigenpres
cell
apc
eg
monophosphoryl
lipid
cpg
oligonucleotid
muramyl
dipeptid
analogu
addit
adjuv
combin
antigen
solubl
membran
protein
provok
strong
specifi
c
immun
respons
final
liposom
may
present
carrier
target
antigen
adjuv
antigenpres
cell
laboratori
industri
procedur
liposom
prepar
establish
liposom
approv
us
food
drug
administr
biomed
applic
potenti
particip
liposomebas
recombin
vaccin
human
veterinari
vaccin
market
promis
benefi
cial
effect
liposom
carrier
consist
abil
ensur
protect
stabilis
antigen
includ
reconstitut
nativ
conform
enhanc
uptak
apc
passiv
activ
target
enhanc
control
antigen
process
uptak
interact
liposom
vaccin
liposom
immunomodul
immun
cell
cooper
innat
adapt
branch
immun
system
schemat
repres
fig
liposomebas
nanoparticl
formul
use
vaccin
broadli
group
sever
class
convent
liposom
compos
neutral
lipid
cholesterol
wide
studi
due
greatest
versatil
desir
formul
paramet
achiev
modifi
cation
lipid
composit
vesicl
prepar
method
liposom
use
steric
entrap
protein
antigen
earli
stage
liposomebas
vaccin
research
classic
liposom
rel
ineffect
enhanc
immunogen
antigen
phospholipid
act
adjuv
adjuv
effect
liposom
base
multimer
present
antigen
adjuv
effect
optimis
variat
lipid
composit
coincorpor
variou
adjuv
molecul
eg
mlpa
mdp
cpg
oligonucleotid
trehalos
dibehen
attach
antigen
transferosom
ultradeform
liposom
enhanc
skin
penetr
properti
compos
phosphatidylcholin
cholat
ratio
presenc
cholat
endow
vesicl
high
elast
enabl
squeez
pore
stratum
corneum
result
high
elast
bilay
vesicl
size
nm
pass
highli
compact
stratum
corneum
deliv
content
deep
part
skin
transferosom
utilis
carrier
system
topic
applic
vaccin
cation
transferosom
also
test
noninvas
topic
vaccin
pdna
vaccin
hepat
b
surfac
adsorpt
cation
liposom
via
electrostat
interact
anoth
use
method
attach
antigen
primarili
protein
liposom
recent
work
christensen
perri
other
protein
antigen
adsorb
cation
ddatdb
dimethyldioctadecylammonium
liposom
demonstr
formul
surfaceadsorb
antigen
highli
stabl
elicit
robust
antibodi
cellmedi
immun
respons
mice
ferret
incorpor
synthet
immunostimulatori
molecul
like
lipophil
tdb
cation
liposom
abl
potenti
signifi
cantli
adjuv
effect
also
observ
certain
cation
lipid
origin
synthesis
transfect
reagent
induc
robust
respons
serum
antitumour
immun
murin
model
pulmonari
metastasi
fi
brosarcoma
dotap
exampl
cation
lipid
use
mani
year
compon
liposom
gene
deliveri
system
exert
enantiospecifi
c
adjuv
effect
dendrit
cell
virosom
special
class
proteoliposom
prepar
reconstitut
infl
uenza
viru
membran
supplement
pc
physicochem
featur
virosom
constrain
welldefi
ned
composit
method
prepar
vesicl
benefi
greatli
inher
deliveri
properti
effi
cient
cell
bind
internalis
cytosol
releas
immunogen
infl
uenza
viru
archaeosom
liposom
prepar
special
lipid
isol
archaebacteria
extremophil
cell
membran
contain
lipid
protein
resist
extrem
temperatur
ph
salt
concentr
lipid
less
sensit
oxid
membran
archaeosom
resist
action
bile
acid
salt
therefor
suitabl
enter
applic
immun
respons
induc
archaeosom
compar
induc
complet
freund
adjuv
functionalis
liposom
gener
repres
variou
liposom
structur
surfac
modifi
ed
variou
ligand
biotin
oligosaccharid
peptid
lipid
reactiv
head
group
ph
temperatur
sensit
polym
monoclon
antibodi
fragment
lectin
etc
tailor
function
respect
select
interact
target
extra
intracellular
structur
eg
pathogen
microorgan
tumour
cell
immun
cell
blood
cloth
target
antigen
antigenpres
cell
great
import
enhanc
effi
caci
subunit
recombin
vaccin
chapter
introduc
new
system
construct
liposomalbas
vaccin
system
employ
metallochel
lipid
bind
histag
recombin
antigen
onto
surfac
liposom
one
critic
paramet
infl
uenc
immunogen
liposom
vaccin
method
antigen
physic
chemic
associ
formul
common
mode
associ
includ
coval
lipid
conjug
either
preor
postvesicl
format
noncoval
surfac
attach
via
biotin
ntanihi
antibodyepitop
interact
encapsul
surfac
adsorpt
fig
mani
earli
studi
liposom
peptid
protein
antigen
mice
compar
encapsul
antigen
conjug
surfac
preform
liposom
earli
studi
alv
gregoriadi
therien
other
confi
rmed
method
gener
effect
induc
antibodi
tcell
respons
associ
protein
antigen
albumin
tetanu
toxoid
case
coval
antigen
conjug
result
superior
antibodi
induct
surpris
bcell
receptor
recognis
intact
antigen
liposom
surfac
size
complex
antigen
decreas
benefi
surfac
conjug
antibodi
induct
becom
pronounc
found
synthet
peptid
surfac
conjug
provid
immun
respons
superior
encapsul
respect
potenti
applic
metallochel
liposom
construct
vaccin
question
vitro
especi
vivo
stabil
great
import
problem
could
divid
two
fi
eld
fi
rst
stabil
liposom
second
effect
compon
present
biolog
fl
uid
eg
protein
ion
stabil
metallochel
bond
exampl
ospc
proteoliposom
gel
permeat
chromatographi
data
indic
good
vitro
stabil
ospc
proteoliposom
chromatograph
process
within
experi
shear
stress
dilut
also
incub
ospc
proteoliposom
serum
demonstr
stabil
metallochel
bond
link
protein
liposom
surfac
fact
vivo
fate
liposom
intraderm
applic
differ
situat
intraven
inject
first
dilut
proteoliposom
intraderm
applic
rapid
second
ratio
tissu
fl
uid
protein
proteoliposom
favour
proteoliposom
owe
rel
high
concentr
site
applic
case
anoth
rout
applic
intraderm
fl
ow
rate
tissu
fl
uid
within
intraderm
extracellular
matrix
even
lower
comparison
muscl
tissu
blood
vessel
fact
often
overlook
stabil
metallochel
bond
probabl
depend
also
charact
particular
protein
shown
liposom
contain
three
function
chelat
lipid
singlechain
fv
fragment
anti
bound
onto
liposom
surfac
abl
target
dendrit
cell
vitro
well
vivo
applic
probabl
endow
metallochel
bond
higher
vivo
stabil
improv
stabil
infl
uenc
higher
immunogen
gener
metal
ion
physicochem
charact
metallochel
lipid
surfac
densiti
belong
factor
could
optimis
get
requir
vivo
stabil
therefor
strong
immun
respons
bind
recombin
ospc
rospc
onto
metallochel
liposom
confi
rmed
tem
gpc
sd
page
dynam
light
scatter
method
stabil
metallochel
bond
model
biolog
fl
uid
studi
incub
rospc
liposom
human
serum
studi
show
h
incub
rospc
still
associ
liposom
base
data
therefor
halflif
rospc
proteoliposom
serum
estim
least
h
increas
stabil
surfaceexpos
antigen
liposom
achiev
chemic
bind
onto
outer
liposom
surfac
appropri
functionalis
respect
potenti
applic
construct
vaccin
question
vitro
especi
vivo
stabil
great
import
refer
report
metallochel
bond
implement
construct
supramolecular
structur
vaccin
carrier
variou
way
associ
protein
antigen
liposom
depict
fig
real
structur
reveal
variou
microscopi
method
present
fig
interact
innat
adapt
immun
respons
paramount
gener
antigenspecifi
c
immun
respons
initi
innat
immun
respons
begin
interact
pathogenassoci
molecular
pattern
pamp
pathogen
side
patternrecognis
receptor
prr
tolllik
receptor
tlr
host
cell
involv
innat
immun
eg
dendrit
cell
major
function
criterion
commonli
use
evalu
variou
new
adjuv
involv
abil
stimul
innat
immun
cell
would
includ
engag
prr
coreceptor
intracellular
adaptor
signal
protein
associ
pamp
deriv
utilis
adjuv
develop
har
power
innat
immun
channel
immun
respons
desir
direct
base
identifi
cation
sever
tlr
pamp
recognis
variou
pamp
agonist
test
adjuv
exampl
tlrpampspecifi
c
interact
includ
bacteri
viral
unmethyl
immunostimul
cpg
oligonucleotid
interact
liposaccharid
compon
monophosphoryl
lipid
mpla
interact
two
type
adjuv
advanc
stage
test
clinic
trial
alreadi
licens
vaccin
contain
mpla
liposom
form
new
lipophil
adjuv
see
fig
suitabl
construct
liposomebas
vaccin
mycobacteri
cord
factor
tdm
synthet
analogu
tdb
potent
adjuv
vaccin
activ
signal
apc
last
group
potent
synthet
semisynthet
adjuv
deriv
muramyl
dipeptid
mdp
muramyl
dipeptid
muropeptid
deriv
specifi
c
group
pamp
repres
peptidoglycan
pgn
gramposit
gramneg
bacteria
contain
pgn
consist
numer
glycan
chain
crosslink
oligopeptid
glycan
chain
compos
altern
nacetylglucosamin
glcnac
nacetylmuram
acid
murnac
amino
acid
coupl
muram
acid
muropeptid
breakdown
product
pgn
bear
least
murnac
moieti
one
amino
acid
one
promin
muropeptid
muramyl
dipeptid
mdp
known
sinc
deal
compound
detail
recent
molecular
base
mdp
recognit
subsequ
stimul
host
immun
system
uncov
myeloid
immun
cell
monocyt
granulocyt
neutrophil
also
dc
possess
two
type
intracellular
receptor
mdpmdp
analogu
name
cryopyrin
infl
complex
two
receptor
recognis
mdpmdp
analogu
minim
recognit
motif
bacteri
cell
wall
peptidoglycan
anoth
recent
report
sensor
mdp
cryopyrin
also
known
member
nodlrr
famili
cryopyrin
part
infl
ammasom
complex
respons
process
activ
form
cleav
precursor
interleukin
therebi
activ
proinfl
ammatori
cytokin
promot
secret
known
strong
endogen
pyrogen
induc
mdp
show
norabumdp
norabugmdp
analogu
pyrogen
even
high
concentr
much
higher
concentr
use
vaccin
express
dendrit
cell
import
respect
applic
mdp
analogu
adjuv
nanoparticl
like
liposom
abl
provid
direct
codeliveri
danger
signal
eg
mdp
togeth
recombin
antigen
therefor
induc
immun
respons
instead
immun
toler
especi
import
weak
recombin
antigen
peptid
antigen
clearli
recognit
mdp
dc
crucial
applic
mdp
analogu
adjuv
within
cell
mdpmdp
analogu
trigger
intracellular
signal
cascad
culmin
transcript
activ
inflammatori
mediat
nuclear
transcript
factor
liposom
probabl
play
role
effici
carrier
mdp
analogu
pathway
extracellular
milieu
cytosol
trigger
intracellular
signal
cascad
culmin
transcript
activ
inflammatori
mediat
nuclear
transcript
factor
pathway
sinc
discoveri
first
synthesi
mdp
one
thousand
variou
deriv
mdp
design
synthesis
test
develop
appropri
drug
immunotherapeut
applic
would
free
side
effect
exert
mdp
main
side
effect
mdp
pyrogen
rigor
headach
fluelik
symptom
hypertens
etc
sever
prepar
reach
stage
clinic
test
mifamurtid
approv
treatment
osteosarcoma
